Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

Dive into a sampling of data drivers—and expanded insights—poised to impact and reshape our annual leaderboard. In this special slideshow presentation, explore a selection of graphical snapshots—a ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected ...

ZERO Prostate Cancer Teams With NASCAR Over Memorial Day Weekend ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...